Cellectis S.A.
CLLS
$3.59
$0.092.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 72.95M | 75.27M | 56.30M | 47.63M | 41.51M |
| Total Other Revenue | 6.64M | 7.28M | 7.14M | 7.12M | 7.71M |
| Total Revenue | 79.59M | 82.55M | 63.44M | 54.75M | 49.22M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 79.59M | 82.55M | 63.44M | 54.75M | 49.22M |
| SG&A Expenses | 19.79M | 19.92M | 19.88M | 18.68M | 19.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -638.00K | -911.00K | -932.00K | -1.24M | -849.00K |
| Total Operating Expenses | 112.67M | 108.96M | 108.65M | 107.59M | 108.77M |
| Operating Income | -33.08M | -26.41M | -45.22M | -52.84M | -59.56M |
| Income Before Tax | -68.02M | -34.84M | -58.54M | -60.27M | -36.76M |
| Income Tax Expenses | -423.00K | 514.00K | 455.00K | 262.00K | 0.00 |
| Earnings from Continuing Operations | -67.59 | -35.35 | -59.00 | -60.53 | -36.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.59M | -35.35M | -59.00M | -60.53M | -36.76M |
| EBIT | -33.08M | -26.41M | -45.22M | -52.84M | -59.56M |
| EBITDA | -21.75M | -13.87M | -33.04M | -41.05M | -48.25M |
| EPS Basic | -0.68 | -0.36 | -0.59 | -0.63 | -0.37 |
| Normalized Basic EPS | -0.43 | -0.13 | -0.28 | -0.30 | -0.14 |
| EPS Diluted | -0.68 | -0.36 | -0.59 | -0.63 | -0.60 |
| Normalized Diluted EPS | -0.43 | -0.13 | -0.28 | -0.30 | -0.16 |
| Average Basic Shares Outstanding | 399.71M | 399.48M | 399.24M | 390.59M | 362.25M |
| Average Diluted Shares Outstanding | 401.09M | 400.86M | 399.24M | 390.59M | 393.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |